The Pathobiology of IL-11 in Kidney Disease: From Epithelial Cell to Fibroblast and Back Again.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

1. Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment.Nature reviews. Cardiology · 2026
   Review
2. The role of IL-11 in chronic diseases.Frontiers in immunology · 2026
   Review
3. Inflammatory bowel disease and renal disorders: from clinical associations to shared mechanisms and management strategies.Frontiers in immunology · 2026
   Review
4. Understanding interleukin 11 as a disease gene and therapeutic target.The Biochemical journal · 2023
   Review

Corrections and comments

• Comment on
  Renal Fibrosis Is Alleviated through Targeted Inhibition of IL-11-Induced Renal Tubular Epithelial-to-Mesenchymal Transition.2023

Authors and funding

2 authors at 1 institution in 2 countries.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as